NICE puts onus on pharma giant after rejecting 'costly' breast cancer drug
The National Institute for Health and Care Excellence has taken the unprecedented step of expressing its “disappointment” with a multinational drug giant in a row over a new breast cancer drug and government’s pricing deal with the pharmaceutical industry.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units